Uncategorized

From sequence to scale: Gene editing’s new era in biologics manufacturing

Published

on

In this episode of Denatured, you’ll hear from Jack Crawford, CEO of Demeetra, and Magnus Gustavsson, chief commercial officer at NorthX Biologics. We unpack the evolution of cell line development — CHO cells, targeted integration, transposases and the collaboration models speeding biologics from sequence to GMP.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version